Vst Articles & Analysis
6 news found
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK viremia (BKV) in adult kidney transplant recipients. ...
ByKalaris
The company also shared progress across its virus-specific T cell (VST) programs, with its lead product, posoleucel, advancing into Phase 3 development for the prevention of infections and disease from six devastating viruses that commonly impact patients following allogeneic hematopoietic cell transplant (allo-HCT) – adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses ...
ByKalaris
Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy 21 of 24 patients were free of clinically significant infections through the Week 14 primary endpoint AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today ...
ByKalaris
Data on ALVR109, a SARS-CoV-2 targeted VST available via compassionate use, further validated the potential of AlloVir’s VSTs for the treatment of respiratory viruses. ...
ByKalaris
This trial extends AlloVir’s VST platform to tackle respiratory viruses that pose a considerable risk for autologous and allo-HCT patients. ...
ByKalaris